Caracterización del riesgo cardiovascular en la diabetes Tipo II período 2014 - 2016-1 en Barranquilla
| dc.contributor.author | Buitrago Jimenez, Lina Maria | |
| dc.contributor.author | Lopera Jinete, Andrea Yuranis | |
| dc.contributor.author | Rivero Torres, Mayra Alejandra | |
| dc.contributor.author | Peña Merlano, Engelbert | |
| dc.date.accessioned | 2018-10-30T20:24:29Z | |
| dc.date.available | 2018-10-30T20:24:29Z | |
| dc.date.issued | 2016 | |
| dc.description.abstract | Introducción La Diabetes Mellitus (DM) es considerada un problema de salud pública a nivel mundial no solo por las complicaciones propias de la patología, sino también por el costo económico que esto genera al sistema de salud. Esta se caracteriza por una deficiencia del páncreas para generar insulina que es una hormona encargada de introducir la glucosa a la célula. Más de un 90% de los individuos diabéticos sufren una DM tipo II, que es un trastorno progresivo con un indicio lento y sutil. Dentro de las complicaciones más frecuentes de esta patología se encuentran las enfermedades cardiovascular, estimada cada año en más de 1 millón de personas afectadas en Estados Unidos y más de 19 millones en el resto del mundo, desencadenando síndrome coronario agudo o la muerte súbita cardiaca. Objetivo: Asociar los factores de riesgo de enfermedad cardiovascular (ECV), en pacientes con diabetes mellitus (DM) tipo II a partir de revisión de historias clínicas para el establecimiento de criterio de manejo clínico; Caracterizar a los pacientes con DM tipo II según el Índice de masa corporal (IMC); Categorizar el grado de obesidad en los pacientes con DM tipo II; Comparar los pacientes diabéticos tipo II que presentan alto de riesgo en el perfil lipídico con los que no presentan. Materiales y métodos: Se realizó un estudio de cohorte retrospectivo a partir de la revisión de historias clínicas en el entro Endocrinológico del Caribe de la ciudad de Barranquilla, Colombia, correspondientes al periodo entre 2014 a 2016. La muestra estuvo representada por 107 mujeres con DM tipo 2 que cumpliesen los criterios de inclusión. Resultados: Obesidad: 49% con obesidad (17% grado 1, 22% grado 2 y 10% grado 3), 32% con sobrepeso, 18% con buen peso y el 1 % con delgadez; p= 0,024, OR= 1,73 e IC 95% 1,07-2,79. Perfil lipídico: 20% óptimo, 40% moderado y 40% alto. Este último con p= 0, 000, OR= 24,38 e IC 95% 12,55-47,37. Conclusiones: Tanto la obesidad como los lípidos elevados son factores de riesgo en los individuos de sexo | spa |
| dc.identifier.uri | http://hdl.handle.net/20.500.12442/2327 | |
| dc.language.iso | spa | spa |
| dc.publisher | Ediciones Univerisidad Simón Bolívar | spa |
| dc.publisher | Facultad de Ciencias de la Salud | spa |
| dc.rights.accessrights | info:eu-repo/semantics/restrictedAccess | |
| dc.rights.license | licencia de Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional | |
| dc.subject | Diabetes | spa |
| dc.subject | Enfermedad Cardiovascular | spa |
| dc.subject | Insulinorresistencia | spa |
| dc.subject | Perfil lipídico | spa |
| dc.title | Caracterización del riesgo cardiovascular en la diabetes Tipo II período 2014 - 2016-1 en Barranquilla | spa |
| dc.type | Other | spa |
| dcterms.references | Seshan SV, Jennette JC. Renal disease in systemic lupus erythematosus with emphasis on classification of lupus glomerulonephritis: advances and implications. Arch. Pathol. Lab. Med., 2009;133 (2) :233-48. | eng |
| dcterms.references | Bihl GR, Petri M, Fine DM. Kidney biopsy in lupus nephritis: look before you leap.Nephrol Dial Transplant. 2006; 21:1749-1752. | eng |
| dcterms.references | Bolton WK, Vaughan ED. A comparative study of open surgical and percutaneous renal biopsies.J Urol 1977; 117:696-8. | eng |
| dcterms.references | Radford MG, Donadio JV, et al. Renal biopsy in clinical practice. Mayo ClinProc 1994; 69:983-4. | eng |
| dcterms.references | Wieckre CG, Golper TA. Complications of percutaneous needle biopsy of the kidney. Am J Nephrol 1982; 2:173-8. | eng |
| dcterms.references | Brissler JJ. Hemothorax as a complication of percutaneous renal biopsy. Am J KidneyDis 1991; 18:122. | eng |
| dcterms.references | Agadjanyan, A.Peterson,J.Noteboom,K.C.O’Briant,A.Allen,D.W.Lin,N. Urban, C.W.Drescher,B.S.Knudsen,D.L.Stirewalt,R.Gentleman,R.L.Vessella, P.S. Nelson,D.B.Martin,M.Tewari,CirculatingmicroRNAsasstableblood- based markersforcancerdetection,Proc.Natl.Acad.Sci.U.S.A.105(2008) 10513–10518. | eng |
| dcterms.references | H.Zhao,J.Shen,L.Medico,D.Wang,C.B.Ambrosone,S.Liu,A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer,PLoS One 5(2010)e13735. | eng |
| dcterms.references | C.Roth,B.Rack,V.Muller,W.Janni,K.Pantel,H.Schwarzenbach,Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer,BreastCancerRes.12(2010)R90. | eng |
| dcterms.references | H.M.Heneghan,N.Miller,A.J.Lowery,K.J.Sweeney,J.Newell,M.J.Kerin,Circulating microRNAs as novel minimally invasive biomarkers for breastcancer, Ann. Surg.251(2010)499–505. | eng |
| dcterms.references | D.D.Taylor,C.Gercel-Taylor,MicroRNA signatures of tumor -derive dexosomes as diagnostic biomarkers of ovarian cancer,Gynecol.Oncol.110(2008)13–21. | eng |
| dcterms.references | Te JL, Dozmorov IM, Guthridge JM, Nguyen KL, Cavett JW, et al. 2010 Identification of Unique MicroRNA Signature Associated with Lupus Nephritis. PLoS ONE 5(5): e10344. | eng |
| dcterms.references | Ruiz-Irastorza G, Khamashta MA, Castellino G, Hughes GR. Systemic lupus erythematosus. Lancet. 2001;357:1027-32. | eng |
| dcterms.references | Austin HA. Clinical evaluation and monitoring of lupus kidney disease.Lupus 1998;7(9):618-621. | eng |
| dcterms.references | Domoto DT. The significance of electron dense deposits in mild lupus nephritis.Yale J BiolMed 1980;53:317-324. | eng |
| dcterms.references | Cameron. Lupus nephritis. J Am SocNephrol 1999; 10(2):413-424 | eng |
| dcterms.references | Hricik, Chung-Park. Glomerulonephritis. New Engl J Med 1998;339(13):888-898. | eng |
| dcterms.references | Golbus J, McCune WJ. Lupus nephritis. Clasification, prognosis, immunopathogenesis and treatment.RheumClin North Am 1994;20:213-224. | eng |
| dcterms.references | Boumpas DT, Balow JE. Outcome criteria for lupus nephritis trials. A criticaloverview. Lupus 1998; 7(9):622-629. | eng |
| dcterms.references | Appel GB, Silva FG, Pirani CL, Melzer JI, Estes D. Renal involvement in systemic lupus erythematosus (SLE): a study of 56 patients emphasizing histologic classification.Medicine. 1978;57:371–408. | eng |
| dcterms.references | Whittier WL, Korbet SM. Renal biopsy: update.CurrOpinNephrolHypertens 2004;13(6):661—5. | eng |
| dcterms.references | Mattix H, Singh AK. Is the bleeding time predictive of bleeding prior to a percutaneous renal biopsy? CurrOpinNephrolHypertens 1999;8(6):715—8. | eng |
| dcterms.references | Hergesell O, Felten H, Andrassy K, Kühn K, Ritz E. Safety of ultrasound-guided percutaneous renal biopsy-retrospective analysis of 1090 consecutive cases.Nephrol Dial Transplant 1998;13(4):975—7. | eng |
| dcterms.references | Schwarz A, Gwinner W, Hiss M, Radermacher J, MengelM,Haller H. Safety and adequacy of renal transplant protocol biopsies.Am J Transplant 2005;5(8):1992—6. | eng |
| dcterms.references | Manno C, Strippoli GF, Arnesano L, Bonifati C, Campobasso N, Gesualdo L, et al. Predictors of bleeding complications in percutaneous ultrasound-guided renal biopsy. KidneyInt 2004;66(4):1570—7. | eng |
| dcterms.references | Eiro M, Katoh T, Watanabe T. Risk factors for bleeding complications in percutaneous renal biopsy. ClinExpNephrol 2005;9(1):40—5. | eng |
| dcterms.references | Stiles KP, Hill C, LeBrun CJ, Reinmuth B, Yuan CM, Abbott KC. The impact of bleeding times on major complication rates after percutaneous real-time ultrasoundguided renal biopsies.J Nephrol 2001;14(4):275—9. | eng |
| dcterms.references | Furness PN, Philpott CM, Chorbadjian MT, Nicholson ML, Bosmans JL, Corthouts BL, et al. Protocol biopsy of the stable renal transplant: a multicenter study of methods and complication rates.Transplantation 2003;76(6):969—73. | eng |
| dcterms.references | Sohal AS, Gangji AS, Crowther MA, Treleaven D. Uremic bleeding: Pathophysiology and clinical risk factors.Thromb Res 2006;118(3):417—22. | eng |
| dcterms.references | John P. Cogswell, et al. Identification of miRNAChanges in Alzheimer's Disease Brain and CSF Yields Putative Biomarkers and Insights into Disease Pathways. Journal of Alzheimer'sDisease. 2008; 14(1): 27-41 | eng |
| dcterms.references | Jessica A. Weber, et al. The MicroRNA Spectrum in 12 Body Fluids.ClinicalChemistry 56: 1733-1741, 2010. | eng |
| dcterms.references | Kohda Y, Murakami H, Moe OW, Star RA. Analysis of segmental renal gene expression by laser capturemicrodissection. KidneyInt. 57(1), 321–331 (2000). | eng |
| dcterms.references | White NM, Fatoohi E, Metias M, Jung K, Stephan C, Yousef GM. Metastamirs: a stepping stone towards improved cancer management. Nat. Rev. Clin. Oncol. 8(2), 75–84 (2010). | eng |
| dcterms.references | Akkina S, Becker BN. MicroRNAs in kidney function and disease. Transl. Res. 157(4), 236–240 (2011). | eng |
| dcterms.references | Li JY, Yong TY, Michael MZ, Gleadle JM. Review: the role of microRNAs in kidney disease. Nephrology (Carlton)15(6), 599–608 (2010). | eng |
| dcterms.references | Castillo PL, Navarro JE, Arango QY, López AA, Mejía VV, González HJ et al. Asociación de obesidad con la enfermedad renal crónica de pacientes atendidos en la Clínica de la Costa. 2005-2014. Rev Colomb Nefrol. 2016; 3 (1):14-19. | eng |
| dcterms.references | Liang M, Liu Y, Mladinov D et al.MicroRNA: a new frontier in kidney and blood pressure research. Am. J. Physiol. Renal Physiol. 297(3), F553–F558 (2009). | eng |
| dcterms.references | Tian Z, Greene AS, Pietrusz JL, Matus IR, Liang M. MicroRNA-target pairs in the rat kidney identified by microRNA microarray, proteomic, and bioinformatic analysis. Genome Res. 18(3), 404–411 (2008). | eng |
| dcterms.references | Sun Y, Koo S, White N et al. Development of a micro-array to detect human and mouse microRNAs and characterization of expression in human organs. NucleicAcids Res. 32(22), e188 (2004). | eng |
| dcterms.references | Zhou H, Cheruvanky A, Hu X et al. Urinary exosomal transcription factors, a new class of biomarkers for renal disease. KidneyInt. 74(5), 613–621 (2008). | eng |
| dcterms.references | Borchers AT, Naguwa SM, Shoenfeld Y, Gershwin ME (2010) The geoepidemiology of systemic lupus erythematosus. AutoimmunRev 9:A277–A287 | eng |
| dcterms.references | Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH et al (1998) Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. ArthritisRheum 41:778–799 | eng |
| dcterms.references | Lang B, Silverman E. A clinical overview of systemic lupus erithematosus in childhood. Pediatrics Review.1993;14:194-20 | eng |
| dcterms.references | Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P et al (2003) Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1, 000 patients. Med (Baltimore) 82:299–308 | eng |
| dcterms.references | Sanchez-Vegazo I, et al. Nefritis lúpica. REV ESP PATOL 2002; Vol 35, n.º 3: 269-27 | spa |
| dcterms.references | Anaya JM, Uribe M, Pinto LF, Matute G, Molina JF, Calle I. Nefritis Lúpica. Definición clínica, patológica y terapéutica. RevColombReumatol 2001; 8: 61-74 | spa |
| dcterms.references | Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. ArthritisRheum 1982; 25:1271-1277 | eng |
| dcterms.references | Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M. Theclassification of glomerulonephritis in systemic lupus erithematousrevisited. J Am SocNephrol 15:241-250, 2004. | eng |
| dcterms.references | Churg J, Bernstein J, Glassock RJ. Lupus nephritis. En: Classification and Atlas of Glomerular Disease, 2nd ed. New York, Igaku-Shoin, 1995, p51. | eng |
| dcterms.references | Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable bloodbased markers for cancer detection. ProcNatlAcadSci U S A 2008;105:10513 | eng |
| dcterms.references | Gilad S, Meiri E, Yogev Y, et al. Serum microRNAs are promising novel biomarkers. PLoSOne 2008;3:e3148. | eng |
| dcterms.references | Hanke M, Hoefig K, Merz H, et al. A robust methodology to study urine microRNAas tumor marker: microRNA-126 and microRNA182 are related to urinary bladder cancer. UrolOncol 2010;28:655–61 | eng |
| dcterms.references | Boeri M. et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc. NatlAcad. Sci. USA 108, 3713–3718 (2011). | eng |
| dcterms.references | RICE P, LONGDEN I, BLEASBY A. EMBOSS: the European Molecular Biology Open Software Suite. TrendsGenet. 2000; 16(6):276-7 | eng |
| dcterms.references | ALTSCHUL S F, GISH W, MILLER W, MYERS E W, LIPMAN D J. Basic local alignment search tool. J. Mol. Biol. 1990; 215:403-410. | eng |
| dcterms.references | GRIFFITHS-JONES S, SAINI HK, VAN DONGEN S, ENRIGHT AJ. miRBase: tools for microRNA genomics. NucleicAcids Res. 2008; 36 D154-D158 (www.mirbase.org). | eng |
| dcterms.references | LI W, GODZIK A. Cd-hit: a fast program for clustering and comparing large sets of protein or nucleotide sequences. Bioinformatics. 2006; 22:1658-9 | eng |
| dcterms.references | K. Zen, C.Y. Zhang, Circulating MicroRNAs: a novel class of biomarkers to diagnose and monitor human cancers, Med. Res. Rev (2010). | eng |
| dcterms.references | J.L. Weickmann, D.G. Glitz, Human ribonucleases. Quantitation of pancreaticlike enzymes in serum, urine, and organ preparations, J. Biol. Chem. 257 (1982) 8705– 8710. | eng |
| dcterms.references | D.J. Gibbings, C. Ciaudo, M. Erhardt, O. Voinnet, Multivesicular bodies associate with components of miRNA effector complexes and modulate miRNA activity, Nat. Cell Biol. 11 (2009) 1143–1149. | eng |
| dcterms.references | H. Valadi, K. Ekstrom, A. Bossios, M. Sjostrand, J.J. Lee, J.O. Lotvall, Exosome mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells, Nat. Cell Biol. 9 (2007) 654–659. | eng |
| dcterms.references | H. Iguchi, N. Kosaka, T. Ochiya, Secretory microRNAs as a versatile communication tool, Commun. Integr. Biol. 3 (2010) 478–481. | eng |
| dcterms.references | G. Camussi, M.C. Deregibus, S. Bruno, V. Cantaluppi, L. Biancone, Exosomes/microvesicles as a mechanism of cell-to-cell communication, Kidney Int. 78 (2010) 838–848. | eng |
| dcterms.references | V. Muralidharan-Chari, J.W. Clancy, A. Sedgwick, C. D’Souza-Schorey, Microvesicles: mediators of extracellular communication during cancer progression, J. Cell Sci. 123 (2010) 1603–1611. | eng |
| dcterms.references | K. Wang, S. Zhang, J. Weber, D. Baxter, D.J. Galas, Export of microRNAs and microRNA-protective protein by mammalian cells, Nucleic Acids Res. 38 (2010) 7248–7259. | eng |
| dcterms.references | N. Kosaka, H. Iguchi, Y. Yoshioka, F. Takeshita, Y. Matsuki, T. Ochiya, Secretory mechanisms and intercellular transfer of microRNAs in living cells, J. Biol. Chem. 285 (2010) 17442–17452. | eng |
| dcterms.references | H. Valadi, K. Ekstrom, A. Bossios, M. Sjostrand, J.J. Lee, J.O. Lotvall, Exosomemediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells, Nat. Cell Biol. 9 (2007) 654–659. | eng |
| dcterms.references | M.P. Hunter, N. Ismail, X. Zhang, B.D. Aguda, E.J. Lee, L. Yu, T. Xiao, J. Schafer, M.L. Lee, T.D. Schmittgen, S.P. Nana-Sinkam, D. Jarjoura, C.B. Marsh, Detection of microRNAexpression in human peripheralbloodmicrovesicles, PLoSOne 3 (2008) e3694. | eng |
| dcterms.references | A. Michael, S.D. Bajracharya, P.S. Yuen, H. Zhou, R.A. Star, G.G. Illei, I. Alevizos, Exosomes from human saliva as a source of microRNA biomarkers, Oral Dis. 16 (2010) 34–38. | eng |
| dcterms.references | I. Dimov, L. JankovicVelickovic, V. Stefanovic, Urinary exosomes, ScientificWorldJournal 9 (2009) 1107–1118. | eng |
| dcterms.references | D.M. Pegtel, K. Cosmopoulos, D.A. Thorley-Lawson, M.A. van Eijndhoven, E.S. Hopmans, J.L. Lindenberg, T.D. de Gruijl, T. Wurdinger, J.M. Middeldorp, Functional delivery of viral miRNAs via exosomes, Proc. Natl. Acad. Sci. U. S. A. 107 (2010) 6328–6333. | eng |
| dcterms.references | Mendinueta Martínez M, Herazo Beltrán Y. Factores de Riesgo Cardiovasculares en Trabajadores de una Empresa Productora de Grasas y Aceites Vegetales. Cienc. innov. salud. 2015; 3(1):23–26. DOI 10.17081/innosa.3.1.235 | spa |
| dcterms.references | Valdés DO, Chávez PE, Torres BF. Comportamiento de las crisis hipertensivas en un grupo de pacientes hipertensos. Cienc. innov. salud. 2014; 2 (1):44-45. DOI 10.17081/innosa.2.1.72 | spa |
| dcterms.references | Velez C, Vidarte JA. Discapacidad y Determinantes Sociales de la Salud Estructurales e Intermedios: Diferencias por Género. Cienc. innov. salud. 2014; 2 (2):63 – 69. DOI 10.17081/innosa.2.2.42 | spa |
| dcterms.references | García Puello F. Autopercepción de Salud y Envejecimiento. Cienc. innov. salud. 2013; 1(1):69-77. DOI 10.17081/innosa.1.1.87 | spa |
| sb.programa | Medicina | spa |
| sb.sede | Sede Barranquilla | spa |
Archivos
Bloque original
1 - 1 de 1
Cargando...
- Nombre:
- CaracteridelriesardiovascudiabeTipIperiodo2014Barranquilla.pdf
- Tamaño:
- 315.75 KB
- Formato:
- Adobe Portable Document Format
- Descripción:
Bloque de licencias
1 - 1 de 1
No hay miniatura disponible
- Nombre:
- license.txt
- Tamaño:
- 1.71 KB
- Formato:
- Item-specific license agreed upon to submission
- Descripción: